Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 16 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Nivolumab for treating advanced clear cell renal cell carcinoma after systemic treatment	Nivolumab (Opdivo; BMS-936558; ONO-4538)	Renal cell carcinoma (RCC)	Renal Cancer	2024	View \| Download
Nivolumab in combination with cabozantinib for metastatic renal cell carcinoma – first-line	Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Renal cell carcinoma (RCC)	Renal Cancer	2019	View
Nivolumab with ipilimumab adjuvant therapy for renal cell carcinoma	Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Renal cell carcinoma (RCC)	Renal Cancer	2022	View \| Download
Pembrolizumab for renal cell carcinoma - adjuvant therapy post nephrectomy	Pembrolizumab (Keytruda; MK-3475)	Renal cell carcinoma (RCC)	Renal Cancer	2020	View \| Download
Pembrolizumab in combination with Axitinib for Metastatic Renal Cell Carcinoma – first line	Axitinib (Inlyta; AG-013736) , Pembrolizumab (Keytruda; MK-3475)	Renal cell carcinoma (RCC)	Renal Cancer	2018	View \| Download
Savolitinib for MET-driven, unresectable and locally advanced or metastatic papillary renal cell carcinoma	Savolitinib (AZD6094)	Renal cell carcinoma (RCC)	Renal Cancer	2019	View \| Download